Frontiers | Correction: Overcoming chemoresistance in esophageal cancer with synergistic strategies
Furthermore, chemotherapy remains a fundamental component of current combination therapies (5‑7).
This correction clarifies a typographical error in the original article, ensuring accurate citation of chemotherapy’s role in esophageal cancer treatment.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Quercetin suppresses the progression of HBV-associated hepatocellular carcinoma by modulating the EGFR signaling pathway
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Surgical treatment of hepatocellular carcinoma: expert consensus statement
- Loco-regional treatment of hepatocellular carcinoma
- Real‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort